McLeod featured in University marketing campaign
Document Actions
Amanda H. Corbett PharmD, BCPS
Clinical Assistant Professor
Division: Pharmacotherapy and Experimental Therapeutics
UNC School of PharmacyDivision of Pharmacotherapy
CB # 7569
Kerr Hall, room 3317
Chapel Hill , NC 27599-7360
Biography:
In addition to her appointment in the School of Pharmacy, Dr. Corbett is also a Clinical Assistant Professor in the School of Medicine, a Clinical Associate for the UNC Center for AIDS Research, and a member of the AIDS Clinical Trials Group (ACTG) Translational Research and Drug Development Scientific Committee and a pharmacologist for the ACTG. She received a B.S. in Chemistry at UNC-Chapel Hill in 1994, a Doctor of Pharmacy degree from Campbell University in 1999, and Pharmacy Practice Residency training at Wake Forest University Baptist Medical Center before completing an ID Specialty Residency and HIV Pharmacology Fellowship at UNC-Chapel Hill under the mentorship of Dr. Angela Kashuba. During her fellowship she received the American College of Clinical Pharmacy Infectious Diseases Fellowship Award and the Infectious Diseases Society of America Travel Award.
Dr. Corbett joined the faculty at UNC School of Pharmacy in 2003 where she leads translational research efforts in antiretroviral use and treatment of opportunistic infections in resource poor countries. Her research efforts have been recognized by awards from the American College of Clinical Pharmacy Infectious Diseases Investigator Development Research Award and the UNC Center for AIDS Research Developmental Award, the UNC Research Council Junior Development Award and Research Grant, and the UNC School of Pharmacy SEED Grant. Most recently she received the Pam Herriott award from the UNC Center for AIDS Research for her outstanding collaborative clinical and research efforts with that group.
Dr. Corbett’s responsibilities include teaching (didactic and precepting) clinical practice (UNC ID clinic), and clinical research (HIV pharmacology of antiretrovirals in developing countries). Current endeavors have included pharmacokinetic comparisons of generic and trade antiretrovirals in both adults and children in Malawi, Africa. Additional projects in Malawi have evaluated the concentrations of antiretrovirals in mothers and infants for the prevention of mother to child transmission and treatment of tuberculosis and cryptococcal meningitis in HIV infected adults and children. Dr. Corbett has published nineteen peer-reviewed manuscripts, including eight original research articles, seven invited reviews/editorials, and four book chapters.
Research Interests:
Pharmacology of antiretrovirals and opportunistic infection therapies in resource poor countries.
Publications
1. McRae MP, Rezk N, Bridges A, Corbett A, Tien H-C, Brouwer K, and Kashuba ADM. Plasma bile acid concentrations in HIV infected subjects taking protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy 2009 [in press].
2. Corbett AH, Hosseinipour M, Nyirenda J, Kanyama C, Rezk N, Mkupani P, Sichali D, Tien H, Kashuba A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian Children. [Antiviral Therapy, under review].
3. Corbett A, Yeh R, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in Pharmacotherapy: A Pathophysiological Approach and Pharmacotherapy Principles and Practice (7th Edition-in press).
4. Pastakia S, Corbett A, Raasch R, Napravnik S, Correll T. Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. July 2008. http://www.medscape.com/viewarticle/576143
5. Pastakia S, Corbett A, Raasch R, Napravnik S, Correll T. High frequency of HIV-related medication errors and associated risk factors in hospitalized patients. Annals of Pharmacotherapy 2008;42(4):491-7.
6. Corbett A. Opportunistic Infections in HIV Infected Patients in 9th Edition of Applied Therapeutics : The Clinical Use of Drugs (2008).
7. Jung B, Rezk N, Bridges A, Corbett A, Kashuba A. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007;21:1095-1104.
8. Dumond J, Yeh R, Patterson K, Corbett A, Jung B, Rezk N, Bridges A, Stewart S, Cohen M, Kashuba A. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007;21(14):1899-907.
9. Corbett A, Yeh R, Dumond J, Kashuba A. Human Immunodeficiency Virus Infection in Pharmacotherapy: A Pathophysiological Approach and Pharmacotherapy Principles and Practice (6th Edition).
10. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, and Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV infection in Malawi. AIDS 2007;21(1):59-64.
11. Corbett AH, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba ADM. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. Antimicrob Agents Chemother 2006;50:2756-61.
12. Corbett A, Yeh R, Dummond J, Kashuba A. Human Immunodeficiency Virus in Pharmacotherapy Principles and Practices.
13. Min SS, Corbett AH, Rezk NL, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba ADM. Protease inhibitor and non-nucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. J Acquir Immun Defic Syndr 2004;37:1577-80.
14. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba ADM. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immun Defic Syndr 2004;36:921-928.
15. Catanzaro L, Corbett A, Kashuba A, Shafer R, Hewitt RG, Acosta E, and Morse GD. HIV-1 Protease Inhibitors, in Antimicrobial Therapy and Vaccines, Vol. II. Yu VL, et al. (eds), New York: Apple Trees Production, 2003.
16. Corbett AH, Kashuba ADM. Ask the Experts - Combining Saquinavir with Lopinavir/ritonavir. www.medscape.com, Sept 2002.
17. Corbett AH, Lim ML, Kashuba, ADM. KaletraÔ (Lopinavir/Ritonavir). Annals of Pharmacotherapy, 2002;36(7/8):1193-1203.
18. Corbett AH, Kashuba ADM. Fosamprenavir. Current Opinion in Investigational Drugs, 2002;3(3):384-390.
19. Corbett AH, Kashuba ADM. Ask the Experts – Treatment of Nelfinavir-Associated Diarrhea. www.medscape.com, Jan 2002.
20. Corbett AH, Rublein JC. DAPD. Current Opinion in Investigational Drugs, 2001;2(3):348-353.
Presentations
1. Corbett A, Hosseinipour M, Nyirenda J, Knayama C, Mshali I, Chinyama S, Lyke A, Rezk N, Hoffman I, Kashbua A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics (PK) Of Trade and Generic Liquid and Split Tablet Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-Infected Malawian Children. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC 2005 [Poster H-1106].
2. Hosseinipour, MC, Corbett AH, Kanyama C, Mshali I, Chinyama S, Phakati S, Rezk N, White S, Hoffman I, Van der Horst C, Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian subjects. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA 2005 [Poster 631].
3. Corbett AH, Davidson L, Park J, Patterson K, Eron JJ, Ngo L, Lim ML, Shelton M, Wire MB, and Kashuba ADM. Dose separation strategies to overcome the pharmacokinetic (PK) interaction of a triple protease inhibitor regimen containing fosamprenavir (908), lopinavir (LPV), and ritonavir (RTV). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA 2004 [Poster 611].
4. Corbett AH, Eron JJ, Fiscus SA, Rezk N, and Kashuba A. Pharmacokinetics, Efficacy, and Safety of a Triple Protease Inhibitor Salvage Regimen Containing Amprenavir/Saquinavir/Ritonavir. American College of Clinical Pharmacy, Annual Meeting, Atlanta, GA 2003 [Platform Presentation].
5. Corbett A, Eron J, Diebold M, Fiscus S, Rezk N, Kashuba A. Short-term
Safety and Efficacy of An Amprenavir [APV] /Saquinavir [SQV] /Ritonavir [RTV]
Salvage Regimen. Infectious Diseases Society of America, Chicago, IL 2002 [Poster 450].
6. Corbett A, Eron J, Rezk N, Diebold M, Kashuba A. A Triple Protease Inhibitor
[PI] Salvage Regimen of Amprenavir [APV] + Saquinavir [SQV] + Ritonavir
[RTV]: Steady State [SS] Pharmacokinetics [PK] and Initial RNA and CD4
Response. World AIDS Conference, Barcelona, Spain 2002 [Poster 4464].
7. Min SS, Corbett AH, Rezk N, Fiscus SA, Cohen MS, Kashuba ADM.
Differential Penetration of Protease Inhibitors [PI] and Non-Nucleoside Reverse
Transcriptase Inhibitors [NNRTI] into the Female Genital Tract [GT]. World
AIDS Conference, Barcelona, Spain 2002 [Poster 5966].
8. Kashuba ADM, Min SS, Corbett AH, Rezk N, Cohen MS. Comparison of
Protease Inhibitor [PI] and Non-Nucleoside Reverse Transcriptase Inhibitor
[NNRTI] Concentrations [CONC] in the Male [M] and Female [F] Genital Tract
[GT]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy,
Washington DC, 2002 [Poster 5.3].
Departments:
- Pharmacy Practice and Experiential Education:
- Clinical Assistant Professor